TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04081012
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo group will receive a similar volume of normal saline as a placebo at the same time intervals.
Study: NCT03812172
Drug: 99mTc-PYP or 99m Tc-HDP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-25 mCi of 99mTc-PYP (or 99m Tc-HDP) will be administered intravenously and imaging will be performed after 3 hours.
Study: NCT03882801
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Periods 1 and 2 (7 days each) participants receive 4 tablets of placebo QHS.
Study: NCT02078609
Drug: LGH447
Approvals — FDA: no, EMA: no, PMDA: no
Description: LGH447 in patients with AML or MDS
Study: NCT03015948
Drug: SHR4640
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single dose of SHR4640 (n=8) for each dose cohort
Study: NCT03015948
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single dose of placebo (n=2) for each dose cohort .
Study: NCT01534715
Drug: IMGN529
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01267136
Drug: Codeine with acetaminophen
Normalized name: acetaminophen / codeine Oral Tablet [Tylenol with Codeine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid codeine/acetaminophen (Capital® 5mL= 120mg acetaminophen/12 mg codeine) 0.72 mg/kg \[=0.3 mL/kg\] (max. 36 mg) PO Q6h, plus 0.72 mg/kg (max. 36 mg) PO Q3h pro re nata (PRN) (max. of 3 PRN doses/day)
Study: NCT03194555
Drug: Low-Dose Naltrexone and Acetaminophen Combination
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Twice daily
Study: NCT02555358
Drug: docetaxel,0xaliplatin,capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: docetaxel 60mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14; oxaliplatin 130mg/m2， ivgtt，2h，d1;q21d
Study: NCT02555358
Drug: oxaliplatin,capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin 130mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14;q21d
Study: NCT01620047
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 3 µg/ml continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU)through a femoral nerve sheath catheter.
Study: NCT01620047
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.9% normal saline delivered through a femoral nerve sheath catheter in addition to a continuous intravenous infusion of fentanyl 3 µg/ml via a PCA pump for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
Study: NCT03194555
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily
Study: NCT00382863
Drug: Optimal Medical/Device Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal Medical/Device Therapy - For the purpose of the PEERLESS-HF study, optimal medical therapy is defined as the use of ACE inhibitors and Beta blockers in the highest tolerable doses for three months prior to study enrollment, and Optimal device therapy is defined as CRT or CRT-D for at least three months prior to study enrollment, when indicated.
Study: NCT00292370
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind placebo taken with OL paroxetine
Study: NCT00449787
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen 500mg tablet
Study: NCT01933516
Drug: GP2013
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP2013
Study: NCT00151073
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00000437
Drug: Placebo Tablet and Placebo Patch
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02040012
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00782379
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 14.5 mg/kg infused over 1-2 hours once daily on 2 consecutive days (days -3,-2).
Study: NCT00458705
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04226105
Drug: GP40081
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml of the GP40081 contains 100 units soluble insulin aspart/protamine-crystallised insulin aspart in the ratio 30/70. Insulin aspart 30 mix is self-administered drug by SC injection 1-3 times per day before meal intake.
Study: NCT01872182
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily twice for 12 weeks
Study: NCT02284854
Drug: BIA 2-093
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02070380
Drug: MultiHance 0.1 mmol/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MultiHance administered at 0.1 mmol/kg
Study: NCT02070380
Drug: MultiHance 0.05 mmol/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MultiHance administered at 0.05 mmol/kg
Study: NCT02553473
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02553473
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002809
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002809
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04498273
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be contacted either electronically or by telephone within 24 hours of randomization to confirm receipt of the study treatment. Study placebo will be shipped to subjects home. Subjects will take placebo twice a day; once in the morning and once in the evening for 45 days. Subjects will be contacted (electronic or telephone) minimally weekly after initial start of study medication and contact will continue up to day 75 after starting study treatment. Follow up electronic contact will be dependent on initial patient response, compliance with response, and medication adherence, for the trial duration using electronic contacts and through telephone contacts. Participants will be queried for any clinically relevant endpoints, especially major bleeding, or need to seek healthcare attention for any reason. Follow-up will occur from the time of study drug receipt and through the 30 day safety period.
Study: NCT01517373
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of tablets and capsules, a total of 3 pills/dose, administered once daily for 84-days
Study: NCT00470808
Drug: POMx
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04026958
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin will be dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
Study: NCT04026958
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo to match clarithromycin will be dosed as 500 mg twice daily, once upon awakening and once with lunch, for 14 days.
Study: NCT01396785
Drug: 33525
Normalized name: POUCH,CLOSED,KARAYA SEAL H#3325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily for 14 days
Study: NCT01396785
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily for 14 days
Study: NCT04492293
Drug: ICP-192
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICP-192 is a white, round, uncoated table
Study: NCT03109392
Drug: Nebulized Lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 ml of 4% lignocaine will be administered via nebulization prior to bronchoscopy
Study: NCT03109392
Drug: Combined spray and nebulization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 2.5 ml of 4% lignocaine via nebulization prior to bronchoscopy and 2 puffs of 10% (10mg/puff) lignocaine spray sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
Study: NCT01272219
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide placebo for 12 weeks (until week 68).
Study: NCT01272219
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide placebo, subcutaneous (under the skin) injection once daily for 160 weeks.
Study: NCT03814629
Drug: Weifuchun
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment group（Weifuchun group）was given Weifuchun tablets, 4 tablets each time, 3 times a day, and 1 hour after meals. The control group(vitamin group) was given vitamin tablets (0.2 g), 4 tablets each time, 3 times a day, and 1 hour after a meal.
Study: NCT01796951
Drug: Celecoxib 200 mg BID
Normalized name: celecoxib 200 MG
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In this single-arm trial, participants will take celecoxib 200 mg BID for 5 doses, followed by aspirin 325 mg daily for 10 days, followed by combination of celecoxib 200 mg BID for 5 doses and aspirin 325 mg daily for 3 days.
Study: NCT02045797
Drug: GSK2140944 Lyophile
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2140944 Lyophile (pale yellow to grayish yellow cake) containing 750 mg of GSK2140944 (as free base) per vial for IV infusion.
Study: NCT02045797
Drug: GSK2140944 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2140944 500 mg capsules will be supplied as pink hard gelatin capsule with no external markings filled with slightly agglomerated pale yellow to grayish yellow powder.
Study: NCT01599871
Drug: theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: theophylline 100 mg, twice at day
Study: NCT03540485
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily administration of 100 mg of melatonin orally, for 24 months, single dose of melatonin between 10pm to 11pm
Study: NCT04105634
Drug: FNOS
Normalized name: Fluvoxamine
DrugBank: Fluvoxamine (DB00176)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The imaging drug used for this group is called 18F-NOS, it is an experimental imaging drug that has not yet been approved by the Food and Drug Administration (FDA) for use except in a research study. Subject will not receive the results or feedback from the study participation, the images may be reviewed with subject or her/his doctor upon request but will not be used to make decisions about subject medical care.
Study: NCT00077012
Drug: QLT0074
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00077012
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02775734
Drug: N-acetyl-cysteine
Normalized name: Dendrimer N-acetyl-cysteine
DrugBank: Acetylcysteine zidrimer (DB16496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-cysteine + Clomiphene citrate + Laparoscopic ovarian drilling
Study: NCT01837095
Drug: POL6326
Approvals — FDA: no, EMA: no, PMDA: no
Description: POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin
Study: NCT01885338
Drug: Inactive placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04091438
Drug: TAK-925 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-925 placebo-matching IV infusion.
Study: NCT04365270
Drug: Glass Ionomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glass ionomer filling material would be modified accordingly or used as is
Study: NCT02677922
Drug: AG-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT00951873
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of long acting activated recombinant human factor VII placebo subcutaneously (under the skin). Each treatment dose of 0,1 mg/kg, 0,3 mg/kg and 0,5 mg/kg is assessed for safety before escalating to next dose.
Study: NCT02656173
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT03073070
Drug: biotin labeled RBCs
Normalized name: Biotin
DrugBank: Biotin (DB00121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Autologous red blood cells are biotin labeled and transfused to the subjects. Survival of these red blood cells is tracked through examination of blood samples until no biotin-labeled red blood cells is detectable.
Study: NCT03566667
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care
Study: NCT03681093
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily administered orally as tablet
Study: NCT02267525
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03113188
Drug: CBP501
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBP501, CDDP plus Nivolumab
Study: NCT02327143
Drug: LY2835219
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02327143
Drug: ¹³C₈-LY2835219
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT00276380
Drug: EGb761
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb761 (Tanakan) 40 mg tablets (2 tablets t.i.d. (3 times a day)) 240 mg/day for 6 months.
Study: NCT00276380
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 40 mg tablets (2 tablets t.i.d.) 240 mg/day for 6 months.
Study: NCT00276380
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 325 mg/day (1 tablet once daily), for 6 months.
Study: NCT03177798
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive either Icatibant or placebo in the first study day. After a washout period of 3 weeks, participant will receive the other treatment. Icatibant (50µg/kg/h) or placebo will be infused for 1 hour prior to the initiation of dialysis and continue through hemodialysis. Hemodialysis session will last approximately 4 hours. Two hours after the end of hemodialysis, the investigators will evaluate mitochondrial function by 31 phosphorus magnetic resonance spectroscopy.
Study: NCT02172651
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take five placebo capsules once daily for 7 days, followed by one placebo capsule once daily until surgery.
Study: NCT04278924
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-079 placebo-matching SC injection.
Study: NCT01725282
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching tablets
Study: NCT04544111
Drug: PDR001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg IV every 4 weeks
Study: NCT04652882
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsule
Study: NCT03515304
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously using an autoinjector/pen in NSTEMI patients within 24 hours, or one day, of admission.
Study: NCT00980629
Drug: M516102
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice a day
Study: NCT00980629
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice a day
Study: NCT03004495
Drug: CHF5259 + placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: b.i.d. for 14 days
Study: NCT03004495
Drug: CHF6001 + placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: b.i.d. for 14 days
Study: NCT01409200
Drug: Antiandrogen Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given per standard of care
Study: NCT03594656
Drug: Ganoderma
Normalized name: GANODERMA LUCIDUM STEM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8g twice daily
Study: NCT03594656
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8g twice daily
Study: NCT00663195
Drug: spironolactone + furosemide
Normalized name: furosemide / spironolactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16 weeks
Study: NCT02349477
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: a pill that looks exactly like the active medication but does not contain medication
Study: NCT04569825
Drug: Ophtamesone
Approvals — FDA: no, EMA: no, PMDA: no
Description: local application intranasally as drops
Study: NCT02813512
Drug: ADSCs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous ADSCs
Study: NCT00406731
Drug: Physiologic saline solution (placebo control)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion over 20 minutes; twice on 1 study day
Study: NCT02633527
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered once daily
Study: NCT02633527
Drug: 100mg SPN-812
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg SPN-812 was administered once daily and compared to placebo
Study: NCT02633527
Drug: 200mg SPN-812
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg SPN-812 was administered once daily and compared to placebo
Study: NCT02633527
Drug: 300mg SPN-812
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg SPN-812 was administered once daily and compared to placebo
Study: NCT02633527
Drug: 400mg SPN-812
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg SPN-812 was administered once daily and compared to placebo
Study: NCT01674361
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to bitopertin once daily orally.
Study: NCT01248468
Drug: Aspirin, acetaminophen and caffeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets each containing Aspirin (250mg), acetaminophen (250mg) and caffeine (65mg)
Study: NCT01248468
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00801255
Drug: RO5024048
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg po bid/100mg po q8h for 7 days
Study: NCT03813121
Drug: placebo intravenous infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single placebo infusion
Study: NCT00468546
Drug: MabThera/Rituxan
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1
Study: NCT00468546
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2
Study: NCT03867084
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of 0.9% normal saline.
Study: NCT01487161
Drug: TCA IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 1 mL intra-articular injection
Study: NCT01269320
Drug: Femarelle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study treatment will consist of Femarelle, two 530mg oral tablets (equivalent to 322 mg of DT56a and 108 mg of Linum Usitatissimum extract each) twice a day for 90 days
Study: NCT00489476
Drug: Staccato Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo aerosol inhalation (0mg)
Study: NCT02098473
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00619398
Drug: FK506MR capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02423954
Drug: Irinotecan + capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01608308
Drug: IV Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000mg IV acetaminophen over 15 minutes every 4 hours for up to 2 doses.
Study: NCT01608308
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of 0.9% normal saline over 15 minutes in place of IV acetaminophen.
Study: NCT01962753
Drug: 18FAV45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Admnistration of 18FAV45 if patient is compliant with one of those treatment: Seroplex, Zoloft, Deroxat, Venlafaxine, Mirtazapine, Moclamine,
Study: NCT03288259
Drug: Local Anesthetics,Topical
Normalized name: LOCAL ANESTHETICS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will be carried out topical anesthesia of the pharynx with lidocaine spray (10%) 6 puffs and instillation of nasal vasoconstrictor 4 drops.
Study: NCT04146207
Drug: SHR0302
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR0302 po QD
Study: NCT02181413
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib citrate placebo-matching capsules
Study: NCT00890656
Drug: Cyclophosphamide (CTX)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m\^2 by vein (IV) over 3 hours every 12 hours for 6 doses days 1, 2, 3 of
Study: NCT00890656
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m\^2 by vein (IV) over 24 hours
Study: NCT00890656
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m2 by vein (IV) over 2 hours followed by 800 mg/m2 over 22 hours on day 1
Study: NCT01924065
Drug: Oral Anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: warfarin, dabigatran etexilate, rivaroxaban, apixaban, edoxaban usage
Study: NCT01460537
Drug: BAY80-6946
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalated dose starting from 0.6 mg/kg in 100 mL of 0.9% NaCl as 60-minutes IV infusion
Study: NCT01460537
Drug: BAY80-6964 fixed dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY80-6946 IV infusion at the maximum tolerated dose determined in Treatment A over 60 min. \[If Treatment A MTD is not tolerable, further subject enrollment will begin at one BAY80-6946 Dose Level lower with the cisplatin-gemcitabine doses remaining constant.\]
Study: NCT01444924
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo block will be placed in a similar manner, using a standardized ultrasound-guided approach. The placebo injection will consist of 30 mL sterile, preservative-free saline.
Study: NCT03662620
Drug: Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg
Normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: White colored oval three-layer tablet
Study: NCT03662620
Drug: Telmisartan 80mg + Amlodipine 5mg + Chlorthalidone 25mg
Normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: White and pink colored oval two-layer tablet